Howard Mayer - 22 Jun 2022 Form 4 Insider Report for Adagio Therapeutics, Inc. (IVVD)

Reporting relationship: Director
Issuer ticker: IVVD
Reported as of: 22 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2022, 16:36:24 UTC
Prior SEC filing: 19 Jan 2022
Next SEC filing: 11 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Jane Henderson attorney-in-fact for Howard Mayer

Key filing fact

Howard Mayer filed Form 4 for Adagio Therapeutics, Inc. (IVVD) on 24 Jun 2022.

Key facts

This page summarizes Howard Mayer's Form 4 filing for Adagio Therapeutics, Inc. (IVVD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jun 2022, 16:36.

Change

Previous filing in this sequence was filed on 19 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IVVD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +75,000
Change %
Price: $0.000000
Shares after: 75,000
Date: 22 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $3.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on June 22, 2022 and vests in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to continued service through the vesting date.